Prof. Khaled Musallam

Director, Thalassemia & Sickle Cell Center; Group Chief Research Officer - Burjeel Medical City

Dr. Khaled Musallam is currently the Group Chief Research Officer at Burjeel Holdings in Abu Dhabi, UAE where he established the clinical research function and operations across the Group’s large hospital network. He is also Director of the Thalassemia & Sickle Cell Center, Founding Director of the Center for Research on Rare Blood Disorder (CR-RBD), Head of the Innovative Trials Unit at the Genetics and Rare Disease Center based at the Group’s flagship hospital, Burjeel Medical City. He is also Global Research Lead at Burjeel Institute for Global Health in New York, Adjunct Professor at Khalifa University in Abu Dhabi, and Adjunct Professor at Weill Cornel Medicine in New York. He has authored over 220 articles on hemoglobin disorders with practice-changing papers in leading international peer-reviewed journals including the New England Journal of Medicine, Lancet, JAMA, Circulation, Blood, among others. His h-index is 61. He is also editor of the Thalassaemia International Federation management guidelines.